|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q3 FY2020
As of Sep 30, 2020
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Short-term investments | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Inventory, net | ||||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||||
| Deposits and other current assets | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Right-of-use lease assets - operating, net | ||||||||||||||||||||
| Deposits and other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Stockholders' Equity (Deficit) | ||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expenses | ||||||||||||||||||||
| Term loan, short-term | ||||||||||||||||||||
| Lease obligation - operating, short-term | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Term loan, long-term | ||||||||||||||||||||
| Revenue purchase and sale liability | ||||||||||||||||||||
| Derivative liability | ||||||||||||||||||||
| Lease obligation - operating, long-term | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders' equity (deficit) | ||||||||||||||||||||
| Common stock, $0.0001 par value; 150,000,000 shares authorized as of June 30, 2025; 50,095,689 and 53,290,227 shares issued and outstanding as of December 31, 2024 and June 30, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||||||||
| Total stockholders' equity (deficit) | ||||||||||||||||||||
| Total liabilities and stockholders' equity (deficit) | ||||||||||||||||||||
Loading...
